High Sensitivity of Late Gadolinium Enhancement for Predicting Microscopic Myocardial Scarring in Biopsied Specimens in Hypertrophic Cardiomyopathy
暂无分享,去创建一个
K. Hayashi | M. Yamagishi | M. Kawashiri | T. Konno | K. Sakata | N. Fujino | Eiichi Masuta | Hiroyuki Nakamura | Y. Nagata | A. Hodatsu
[1] F. Gaita,et al. Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance study. , 2013, International journal of cardiology.
[2] S. Naganawa,et al. Relationship of myocardial fibrosis to left ventricular and mitochondrial function in nonischemic dilated cardiomyopathy--a comparison of focal and interstitial fibrosis. , 2013, Journal of cardiac failure.
[3] B. Wintersperger,et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. , 2013, JACC. Cardiovascular imaging.
[4] B. Maron,et al. Hypertrophic cardiomyopathy – Authors' reply , 2013, The Lancet.
[5] M. Laakso,et al. Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy , 2012, Heart.
[6] Barry J Maron,et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci , 2011, Journal of the American College of Cardiology.
[7] Barry J Maron,et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.
[8] Stefan Neubauer,et al. The interplay between cardiac strain and fibrosis in non‐ischaemic cardiomyopathies: insights from cardiovascular magnetic resonance , 2011, European journal of heart failure.
[9] Pierre Croisille,et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. , 2011, Journal of the American College of Cardiology.
[10] Vivek Muthurangu,et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. , 2011, JACC. Cardiovascular imaging.
[11] J. Seidman,et al. Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy , 2010, Proceedings of the National Academy of Sciences.
[12] Roger R Markwald,et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. , 2010, The Journal of clinical investigation.
[13] M. Sheppard,et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. , 2010, Journal of the American College of Cardiology.
[14] M. Schieber,et al. Comparative Evaluation of Left and Right Ventricular Endomyocardial Biopsy: Differences in Complication Rate and Diagnostic Performance , 2010, Circulation.
[15] S. Heymans,et al. Replacement and reactive myocardial fibrosis in idiopathic dilated cardiomyopathy: comparison of magnetic resonance imaging with right ventricular biopsy , 2010, European journal of heart failure.
[16] R. Rubinshtein,et al. Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy , 2010, Circulation. Heart failure.
[17] M. Beer,et al. Impact of Myocardial Fibrosis in Patients With Symptomatic Severe Aortic Stenosis , 2009, Circulation.
[18] D. Corrado,et al. Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death. , 2009, European heart journal.
[19] D. Pennell,et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. , 2008, European heart journal.
[20] W. Manning,et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. , 2008, Journal of the American College of Cardiology.
[21] M. Jessup,et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. , 2007, Circulation.
[22] W. Manning,et al. Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.
[23] V. Hombach,et al. Myocardial biopsy findings and gadolinium enhanced cardiovascular magnetic resonance in dilated cardiomyopathy , 2006, European journal of heart failure.
[24] Richard B Devereux,et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[25] S. Chugh,et al. Global remodeling of the ventricular interstitium in idiopathic myocardial fibrosis and sudden cardiac death. , 2004, Heart rhythm.
[26] Dudley J Pennell,et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.
[27] K. Schulz,et al. Uses and abuses of screening tests , 2002, The Lancet.
[28] J. Seidman,et al. The Genetic Basis for Cardiomyopathy from Mutation Identification to Mechanistic Paradigms , 2001, Cell.
[29] M. Burch,et al. Hypertrophic cardiomyopathy. , 1994, Archives of disease in childhood.
[30] C Kawai,et al. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. , 1986, British heart journal.
[31] Y. Hamashima,et al. Myocardial Fiber Diameter and Regional Distribution in the Ventricular Wall of Normal Adult Hearts, Hypertensive Hearts and Hearts with Hypertrophic Cardiomyopathy , 1983, Circulation.
[32] 吉田 朱美. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure , 2013 .
[33] K. Hayashi,et al. Impact of reduced left atrial functions on diagnosis of paroxysmal atrial fibrillation: results from analysis of time-left atrial volume curve determined by two-dimensional speckle tracking. , 2011, Journal of cardiology.
[34] O. Simonetti,et al. An improved MR imaging technique for the visualization of myocardial infarction. , 2001, Radiology.
[35] R. Shabetai. Endomyocardial biopsy. , 1989, Giornale italiano di cardiologia.